⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 14, 2024Synfacts

TNG908, a Clinical Candidate for PRMT5 Inhibition Exploiting Synthetic Lethality with MTAP

Antonia F. Stepan Seong Heon Kim

View at Publisher

Ask AI

Bookmark

Share

Abstract

Key words PRMT5 - TNG908 - synthetic lethality - MTAP - brain penetrant - glioblastoma - clinical candidate

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stepan et al. (2024) studied this question.

synapsesocial.com/papers/68e64c3ab6db6435875dc792 https://doi.org/10.1055/s-0043-1774882

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers2024 · 74 citations
2DDDR-10. TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors, including glioblastoma, with MTAP loss2025
3NFS-06. Targeting PRMT5 in MTAP-deleted NF1 high grade gliomas.Original Research · 2025
4The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of <i>MTAP</i> -Deleted CancersEarly-Phase Clinical Trial · 2026 · 2 citations
5Abstract 3901: BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activity and favorable selectivity in tumors with MTAP-deletion.In Vitro Study · 2026

More related papers

Abstract 4486: The MTA-cooperative PRMT5 inhibitor CTS3497 alone and in synergy with mechanism-based combination targeted therapies for the treatment of <i>MTAP</i> -deleted cancers.2026
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers2024
Abstract 4596: Targeting arginine methylome in <i>9p21</i>/<i>MTAP</i>-deleted malignant cancers with a next generation PRMT5-specific inhibitor CTS34972024

More from Synfacts

Asymmetric [4+2] Photocycloaddition of Aminoquinolines with Styrenes to TetrahydroquinolinesWed,
Electrocatalytic Synthesis of cis-Aziridines via Cobalt CatalysisWed,